Investigation of the effectiveness of intradermal botulinum toxin A treatment in the treatment of erythematotelangiectatic rosacea (ETR) using clinical, biophysical, dermatoscopic and videocapillaroscopy.
There is no gold standard treatment for erythematotelangiectatic rosacea (ETR). In recent years, some studies have been conducted to demonstrate the efficacy of intradermal botulinum toxin A (BoNT-A) treatment in ETR and facial erythema. Studies including objective and quantitative measurements are limited. This study aims to investigate the efficacy and safety of intradermal BoNT-A treatment in ETR patients. This randomised, double-blind, split-face study included 30 participants with erythematotelangiectatic rosacea (ETR). They were randomly randomised to intradermal BoNT-A on one side of the face and placebo on the other side. Clinician's erythema assessment (CEA) score, patient self-assessment (PSA) score, erythema index (EI), melanin index (MI), dermatoscopic and capillaroscopic analyses of background erythema and vascular structure were assessed at baseline and one month after treatment.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
30
Intradermal botulinum toxin A was applied to the treatment side
NaCl was injected into the placebo side
Istanbul Training and Research Hospital
Istanbul, Turkey (Türkiye)
Assessment of erythema with Clinician's Erythema Assessment scale
The effect of intradermal BoNT-A treatment on facial erythema was evaluated using the Clinician's Erythema Assessment scale.
Time frame: One month
Evaluation of erythema using mexameter
Evaluation of the effect of intradermal BoNT-A treatment on the objective erythema value measured by mexameter.
Time frame: One month
Evaluation of erythema by dermatoscopy
Evaluation of the effect of intradermal BoNT-A treatment on dermatoscopic background erythema.
Time frame: One month
Evaluation of the change in vascular structure using videocapillaroscopy
The secondary objective of the study was to examine the effect of intradermal BoNT-A treatment on the Investigator Global Assessment (poorly defined vasculature and increased vessel diameter were considered poor response; IGA score=-1, localized or complete obliteration of vascular structures was considered good; IGA score=1, no change in vascular structures was considered no response; IGA score=0) scale developed using videocapillaroscopy.
Time frame: One month
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.